Trial Profile

A Safety, Tolerability, and Pharmacokinetic Study of Single, Escalating Subcutaneous Doses of LY2951742 in Healthy Volunteers.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Galcanezumab (Primary)
Indications Migraine
Focus Adverse reactions; First in man
Sponsors Eli Lilly and Company

Most Recent Events

30 Jun 2013 Results presented at the 2013 International Headache Congress .
18 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
06 Mar 2012 Planned end date changed from 1 Feb 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com